Wave Life Sciences (WVE) is back in focus after recent data updates on its RNA editing platform, where lead program WVE-006 for alpha-1 antitrypsin deficiency showed dose-responsive, durable editing and an encouraging safety profile.

Despite the encouraging WVE-006 data, Wave Life Sciences’ recent share price return has been weak. The stock is at US$6.00 after a 90-day share price decline of 51.85% and a year to date decline of 62.38%, while the 3-year total shareholder return of 50.75% tells a different, longer-term story.

If this kind of biotech volatility has your attention, it could be a useful moment to scan other healthcare-focused AI opportunities using our 41 healthcare AI stocks

With Wave Life Sciences stock sitting at US$6.00 and analyst targets at US$21.94, the gap between price and expectations is wide. Is this a genuine mispricing, or are markets already weighing future growth risks correctly?

Most Popular Narrative: 73% Undervalued

Based on the most followed narrative, Wave Life Sciences stock at $6.00 sits well below an estimated fair value of $22.19, with that gap tied directly to specific assumptions about future trial readouts, margins, and capital needs.

The upcoming clinical data readouts for key programs (AATD with WVE-006 and obesity with WVE-007) in late 2025 and early 2026 represent potential inflection points, supported by strong early efficacy and favorable safety, and, if positive, could significantly expand revenue opportunities in large, underserved markets driven by an aging population and rising chronic disease prevalence.

Curious what sits behind that fair value gap? The narrative leans heavily on rapid revenue expansion, improved margins, and a premium future earnings multiple to justify that number.

Result: Fair Value of $22.19 (UNDERVALUED)

However, the bullish Wave Life Sciences narrative still leans on unpredictable collaboration revenue and a narrow set of high stakes programs where any clinical setback could quickly reset expectations.

Another View: What Wave Life Sciences’ P/S Ratio Is Signalling

The analyst driven fair value of $22.19 paints Wave Life Sciences stock as heavily undervalued, but the current P/S ratio of 16.1x tells a different story. That compares with 5.7x for the US Pharmaceuticals industry, 1.2x for peers, and a fair ratio estimate of just 0.8x.

If the market were to move closer to that fair ratio, investors would be looking at a very different price profile. The real question is which signal you trust more: the growth narrative or the revenue multiple.

Next Steps

Mixed signals on Wave Life Sciences so far? If you want to move quickly and build confidence in your own stance, start by weighing the 1 key reward and 3 important warning signs

Looking for more investment ideas beyond Wave Life Sciences stock?

Do not stop with just one stock. Use these focused screens to quickly spot other opportunities that match the kind of risk and return profile you care about most.

• Target potential bargains by zeroing in on companies flagged as 44 high quality undervalued stocks based on a blend of quality and pricing metrics.
• Build a sturdier core portfolio by hunting for companies in the solid balance sheet and fundamentals stocks screener (48 results) that pair financial strength with consistent fundamentals.
• Scan the screener containing 20 high quality undiscovered gems to find companies that align with your criteria.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.